To leverage the synergy between discovery, education, medicine, and economic development in genomic sciences to improve the human condition around the globe by developing and applying scientific advances to health, agriculture, learning, and commercialization.
Celsion Corporation is a fully integrated biopharmaceutical company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies. Our lead product candidate is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a phase 3 trial combined with RFA for the treatment of hepatocellular carcinoma. It is also in a phase 2 study for the treatment of recurrent chest wall breast cancer. Second in our pipeline is GEN-1, a DNA-mediated immunotherapy for the localized treatment of ovarian cancer.
Celsion has 3 platform technologies providing the basis for the development of a range of therapeutics for difficult-to-treat forms of cancers. With these technologies we are working to develop and commercialize more efficient, effective, and targeted oncology therapies, maximizing efficacy while minimizing side effects common to cancer treatments.
CFD Research Corporation (CFDRC) specializes in engineering simulations and innovative designs for Aerospace, Cyber IA, Defense, Life Sciences, Materials, Energy, and other industries. Using our software and experimental facilities, we develop new hardware concepts, innovative designs, and prototypes. We have over 50 patents awarded or pending in the areas of biotechnology, combustion, propulsion, and materials.
Concero Scientific’s mission is safeguarding the warfighter and the homeland from biothreats by accelerating prevention, response and control solutions for infectious diseases and bioagents through research, development and integration of cutting-edge life science discoveries.
TEM-PCR™ (Target Enriched Multiplex Polymerase Chain Reaction) is a novel multiplex PCR amplification strategy invented by Dr. Jian Han in 2003. Dr. Han had been in China combating the epidemic SARS outbreak at the time and became frustrated with the limitations of traditional PCR. This led him to investigate ways of multiplexing PCR to detect multiple targets. On a flight back to the U.S. from China, Dr. Han conceived of the basic process for achieving true multiplex PCR by implementing nested primers at lower concentrations with the addition of a universal primer set for the large-scale amplification. This process was proven later that year and Dr. Han named it TEM-PCR™.
Diatherix Eurofins founder Dennis Grimaud became involved with TEM-PCR™ soon after its inception. Dr. Han recruited Grimaud to become the CEO of his company, Genaco Biomedical Products, after the invention of TEM-PCR™. From 2005-2008 Genaco participated in multiple studies such as this correlation study demonstrating TEM-PCR™ to be “… both accurate and robust enough to be used in a routine clinical setting.” Also during that time, TEM-PCR™ was named both the Frost and Sullivan award for Technology Innovation and Leadership of the Year and runner up for the Wall Street Journal Medical Technology Innovation of the Year Award. Since 2008, Diatherix Eurofins has been using TEM-PCR™ to develop and perform multiplex PCR panel testing for infectious disease diagnostics. Diatherix Eurofins was the first CLIA certified laboratory to be awarded an Emergency Use Authorization (EUA) from the FDA for H1N1-09 during the 2009 pandemic. Diatherix Eurofins holds all associated rights and patents for TEM-PCR™.
Envision Genomics is committed to improving the quality & reducing the cost of healthcare by unlocking the utility and value of the genomic sequence for patient care.
Envision Genomics is designed to
- Help clinicians and healthcare providers diagnose rare disease, end diagnostic odysseys or reverse misdiagnoses through integration of the practice of genomic medicine when and how they need it.
- Provide partner organizations with the clinical end-to-end expertise, infrastructure and resources necessary to implement and deploy cutting edge, market differentiating clinical genomic services.
- Support practicing preventative care.
A unique research service company providing consulting, laboratory services, and comprehensive biosamples supporting the research and development of new treatments for life-threatening and chronic diseases.
Folio Conversant will offer an extensive array of quality biospecimens, particularly FFPE tissue and blood, supported by comprehensive laboratory and analytic services.
A team of chemical engineers, molecular biologists, physicists, and entrepreneurs are developing a unique approach to solving this problem. GeneCapture, Inc. is developing a rapid diagnostic device to detect and identify the source of an infection in less than 1 hour. The proprietary DNA-based technology has the potential to revolutionize infection control by providing a Point of Care, inexpensive, rapid diagnosis of pathogens in humans, agriculture and animals.
iCubate is a molecular diagnostic company with a novel multiplex polymerase chain reaction (mPCR) technology; an integrated platform for automated sample preparation, amplification and detection – the iCubate System, or iC-System; and a product line for infectious disease diagnostics and research applications.
IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs). As an innovative leader in discovery and application of biomarkers and new targets to monitor and cure IMIDs, we create value through the combination of the world’s largest IMID biobank, extensive relevant clinical expertise, high-throughput genomic and genetic analysis, and intellectual property. IMIDomics is located at Vall d’Hebron Hospital in Barcelona, Spain and on the HudsonAlpha Institute campus in Huntsville, Alabama.
We offer reagents and services to amplify and sequence the immune repertoire with Next Generation Sequencing (NGS). Our primer kits are compatible with both Illumina and Roche 454 sequencing platforms. Read more to discover the best options for meeting your research goals.
6iXpressGenes is a synthetic biology company located at the HudsonAlpha Institute for Biotechnology. Our company specializes in protein services and instrumentation, and protein and genetic engineering research. We support commercial, institutional and academic organizations. We have a special background in extremozymes, microgravity and trace fluorescent labeling. iXpressGenes has exclusive access to a suite of hyperthermophilic genomes from the deep sea vents of the Atlantic Ridge. Proteins and enzymes from these genomes have special qualities that are useful in engineering and metabolic reactions.
<span “font-size:11.0pt;line-height:119%;font-family:calibri;color:#3b3b38;=”” mso-color-ext:134217732;mso-color-extmod:272630260;language:en-us;mso-ansi-language:=”” en-us”=””> Our team has deep experience in microgravity, having conducted several experiments on the International Space Station. These experiments have led us to diffraction studies in both X ray and neutron beam. Years of research in protein crystallization led us to a new technique that is highly effective in finding and discerning leads – trace fluorescent labeling. Our disciplines are in biochemistry, structural genomics and instrumentation.
Through a combination of scientific and technological innovations, Kailos Genetics is advancing genetic testing with its leading-edge professional products and services for clinicians and researchers. Kailos also draws upon this deep experience to make genetic testing accessible and affordable to consumers.
Founded in 2010 and based in Huntsville’s HudsonAlpha Institute for Biotechnology, Kailos has a diversified business model built upon proven, proprietary testing technology that provides affordable, medically relevant genetic testing. Kailos’ professional partners –hospitals, physicians, labs and pharmacies – can either purchase the company’s next-generation sequencing (NGS) technology or they can outsource testing directly to Kailos. Consumer testing provides an additional facet to a robust revenue stream.
Kymanox is Your Life Science Solutions Partner. We are a premier technical products and project management company. We are experts in providing our clients in the Biotechnology, Pharmaceutical, and Medical Device, and Combination Product industries with engineering, scientific, regulatory, and process operations support. We help bring products from bench to patient. We differentiate ourselves by offering a broad range of technical services and products with turnkey project delivery. We serve clients globally from our headquarters in Durham (RTP), North Carolina and branch hubs across the US.
Leavendary offers all-inclusive services to craft brewers, from quality testing and delivery of yeast to testing of brews in progress as well as finished goods.
In diligent pursuit of our goal to advance array-based technologies for biological research, detection and diagnostics, MI creates array products which generate the highest quality microarray data. MI innovations in array-based technologies have been applied in analyte testing, diagnostics, identification of viral and bacterial pathogens, and personalized medicine.
Founded in 1999, MI has its origins in the Microarray Core facility of the Vanderbilt-Ingram Comprehensive Cancer Center in Nashville, Tennessee. As a result of the growing expertise, proficiency and printing innovations developed at the Cancer Center, MI was established as an autonomous company in November 2000. MI has been privately held since May 2010.
In May 2008, MI relocated to the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. This move allowed MI the much needed ability to expand its capacity, as well as foster close relationships in the exciting, growing field of personalized medicine.
MVW Nutritionals is a privately held company, with the mission of providing leading edge nutritional supplements and vitamins for persons who have cystic fibrosis and other gastrointestinal disorders. Formed in 2013, our goal is to deliver innovative products, through continuous improvement, coupled with outstanding service.